The “Buy” Rating of Paratek Pharma Reiterated on yet another event

Paratek Pharmaceuticals (NASDAQ:PRTK)‘s stock had its “buy” rating reaffirmed by analysts at LADENBURG THALM/SH SH in a research note issued on Thursday, May 9th, Stock Target Advisor reports.

Other research analysts have also issued research reports about the company. Zacks Investment Research lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 24th. ValuEngine lowered Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. HC Wainwright reiterated a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Thursday, February 28th. Canaccord Genuity lifted their price target on Paratek Pharmaceuticals from $14.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, January 16th. Finally, Wedbush reiterated an “outperform” rating on shares of Paratek Pharmaceuticals in a research report on Wednesday, March 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Paratek Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $22.25.

 

NASDAQ:PRTK opened at $3.52 on Thursday. The company has a current ratio of 14.06, a quick ratio of 13.95 and a debt-to-equity ratio of 14.48. The stock has a market cap of $117.69 million, a price-to-earnings ratio of -0.99 and a beta of 1.75. Paratek Pharmaceuticals has a 52 week low of $3.42 and a 52 week high of $12.30.

Several large investors have recently made changes to their positions in PRTK. Bank of New York Mellon Corp boosted its position in shares of Paratek Pharmaceuticals by 5.7% during the third quarter. Bank of New York Mellon Corp now owns 136,376 shares of the specialty pharmaceutical company’s stock valued at $1,323,000 after buying an additional 7,332 shares during the period. BlackRock Inc. boosted its position in shares of Paratek Pharmaceuticals by 3.6% during the third quarter. BlackRock Inc. now owns 2,677,154 shares of the specialty pharmaceutical company’s stock valued at $25,967,000 after buying an additional 93,764 shares during the period. Dimensional Fund Advisors LP purchased a new position in shares of Paratek Pharmaceuticals during the third quarter valued at approximately $1,860,000. JPMorgan Chase & Co. boosted its position in shares of Paratek Pharmaceuticals by 6.5% during the third quarter.